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Abstract 
Background: Routine application of vascularized composite allotransplantation (VCA) is 
hampered by immunosuppression-related health comorbidities. To mitigate these we 
developed an inflammation-responsive hydrogel for local immunosuppression. Here we report 
on its long-term effect on graft survival, immunological and toxicological impact. 
Methods: Brown Norway-to-Lewis rat hind limb transplantations were treated either 
systemically with daily injections of 1 mg/kg tacrolimus or with subcutaneous intragraft 
injections of hydrogel containing 7 mg tacrolimus, every 70 days. Animals were monitored 
for rejection or other pathology for 280 days. Systemic and graft tacrolimus levels, regulatory 
T cells, and donor cell chimerism were measured periodically. At endpoint, markers for 
kidney, liver and metabolic state were compared to naïve age-matched rats. 
Results: Both daily systemic tacrolimus and subcutaneous intragraft tacrolimus hydrogel at 
70 day intervals were able to sustain graft survival for >280 days in 5 out of 6 recipients. In 
the hydrogel group, 1 graft progressed to grade 3 rejection at postoperative day (POD) 149. In 
systemic tacrolimus group, 1 animal was euthanized due to lymphoma on POD 275. Hydrogel 
treatment provided stable graft– and reduced systemic tacrolimus levels, and a 4 times smaller 
total tacrolimus dose compared with systemic immunosuppression. Hydrogel-treated animals 
showed preserved kidney function, absence of malignancies or opportunistic infections and 
increased hematopoietic chimerism compared to systemic immunosuppression. 
Conclusions: Our findings demonstrate that localized immunosuppression with tacrolimus 
hydrogel is a long-term safe and reliable treatment. It may reduce the burden of systemic 
immunosuppression in VCA, potentially boosting the clinical application of this surgical 
intervention.  
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Introduction 
Systemically administered tacrolimus (TAC) is the most commonly used immunosuppressant 
in vascularized composite allotransplantation (VCA)
1
. However, of the 66 registered in the 
International Registry on Hand and Composite Tissue Transplantation hand transplant 
recipients, 26% suffered from elevated creatinine values, 32.3% – from opportunistic bacterial 
infections and 3 of them developed malignancies
2
. These TAC-mediated morbidities are a 
barrier to the broader adoption of VCA. Transitioning patients from TAC to other 
immunosuppressants has been attempted, but with limited success
2
. Consequently, the field 
has turned to “increasingly bold approaches in modifying immunosuppression”3, that need 
solid and conclusive preclinical data, demonstrating their feasibility, efficacy and safety.  
Our group developed a graft-targeted inflammation-responsive hydrogel
4-6
 delivering TAC 
“on demand” – only when needed, with the aim to provide an effective future alternative or 
addition to systemic immunosuppression for patients. The hydrogelator – triglycerol 
monostearate (TGMS) – is biocompatible, biodegradable, generally recognized as safe by the 
US Food and Drug Administration, and can be loaded with therapeutically relevant amounts 
of TAC. TAC-loaded TGMS hydrogel (TGMS-TAC) releases TAC in response to 
inflammatory stimuli, and prolongs VCA survival with a single injection
7
.  
Here we hypothesized that repeated subcutaneous intragraft injections of TGMS-TAC 
maintain long-term graft survival in the Brown Norway-to-Lewis rat hind limb 
allotransplantation model. We expected that TGMS-TAC-treated animals would have higher 
TAC concentrations in the graft and lower in the blood compared to daily systemic TAC 
treatment (standard of care), which should result in reduced off-target effects and 
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nephrotoxicity. Furthermore, we were interested in whether TGMS-TAC influences the 
dynamics of effector T cells (Teff), regulatory T cells (Treg), and chimerism. 
 
Materials and Methods: 
Male Brown Norway and Lewis rats (6-8 weeks old weighing 200 to 250 g) were purchased 
from Charles Rivers Breeding Laboratories, Germany. Animals were kept in specific 
pathogen-free conditions. Experiments were planned and carried out in agreement with 
current 3R and ARRIVE guidelines and approved according to Swiss animal protection laws 
by the Veterinary Authorities of the Canton Bern, Switzerland, approval no. BE94/15. 
Brown Norway-to-Lewis rat hind limb transplantations were performed and animals were 
treated either with 1 mg/kg/day TAC systemically in the neck fold or every 70 days with 1 ml 
TGMS-TAC containing 7 mg tacrolimus (n=6 for each group). In the TGMS-TAC group, 4 
subcutaneous TGMS-TAC depots of 250 µL each were injected in the zones of biceps 
femoris, gastrocnemius, tibialis anterior, and vastus muscles, taking great care to distribute the 
amount of drug as evenly as possible intra and interindividually. The reinjection time point 
was chosen based on a pilot study showing that transplanted animals (n=5) treated with a 
single intragraft injection of 1 ml TGMS-TAC loaded with 7 mg TAC on postoperative day 1 
(POD 1) rejected their graft on POD 83.4 ± 6.7. Reinjection time point was defined as 14 days 
before rejection and set to POD 70. Graft rejection was evaluated macroscopically and graded 
as 0 = no rejection, 1 = erythema and edema, 2 = epidermolysis and exudation, and 3 = 
desquamation, necrosis, and mummification.  
Rats were euthanized either once grade 3 rejection was reached or on day 280 (endpoint) . 
Necropsy for immunosuppression-related side effects was performed. Kidney, as well as graft 
skin and muscle histology were evaluated by a blinded pathologist (Hematoxylin and Eosin 
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and/or Periodic acid–Schiff staining, as necessary). Kidney samples were graded according to 
the semiquantitative calcineurin inhibitor toxicity score by Kambham et al
8
. Histological 
grading of skin rejection was according to Banff classification
9
. Additionally skin and muscle 
lymphocyte infiltration, vasculopathy and necrosis were graded as 0 – none, 1 – minimal, 2 – 
moderate, 3 – extensive. Immunofluorescence analyses of IgG, IgM, C3b/c, C4b/c, C5b-9, 
CD45RA in graft skin and muscle were performed. Blood urea nitrogen (BUN) and 
creatinine; cholesterol and triglycerides; aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) as kidney, metabolism and liver markers, respectively, complete 
blood count, and donor-specific antibody formation were assessed in blood at endpoint. 
Throughout the study TAC levels were measured in blood and skin biopsies retrieved from 
grafts and contralateral limbs at selected time points by LC-MS/MS.  
Flow cytometry for obtaining Treg and chimerism levels was performed in blood at selected 
time points, and in graft and contralateral limb skin at endpoint.  
Statistical analyses were executed with Prism software (GraphPad Software Inc., La Jolla, 
CA, United States). Statistically signiﬁcant data were presented as follows: *P<0.05; 
**P<0.01; ***P<0.001; and ****P<0.0001. Statistical tests are speciﬁcally indicated under 
each figure.  
Detailed materials and methods are available in SDC, Materials and Methods, in the online 
version of this article (SDC, http://links.lww.com/TP/B584). 
 
Results 
Periodic TGMS-TAC injections promote long-term VCA survival 
To test if 1 ml TGMS-TAC loaded with 7 mg TAC reinjected every 70 days promotes long-
term graft survival in a rat hind limb transplantation model, we compared TGMS-TAC 
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treatment to daily systemic immunosuppression using TAC at 1 mg/kg/day (Figure 1a). Five 
out of 6 animals survived until endpoint in each group (Figure 1b).  
In the TGMS-TAC group, 1 animal was sacrificed due to grade 3 rejection at POD 149 
(Animal 1, Figure 1c). One animal experienced 3 rejection episodes (Animal 2, Figure 1c). 
One animal started rejecting at POD 262, which reached grade 2 at endpoint (Animal  3, 
Figure 1c). One animal experienced mild rejection, which resolved temporarily and later 
reoccurred (Animal 4, Figure 1c). Two animals had no rejection episodes (Animals 5 and 6, 
Figure 1c). No local complications due to TGMS-TAC-injections were observed in any of the 
rats. In systemic TAC group, 1 animal was euthanized due to lymphoma on POD 275. 
Systemic immunosuppression was sufficient to maintain the grafts rejection-free throughout 
the duration of the treatment (Animals 7-12, Figure 1c). 
Histopathological evaluation of graft skin at endpoint (POD 280) revealed no necrosis in any 
of the animals (Animals 1-12, Figure 1d). Two TGMS-TAC-treated animals were classified as 
Banff grade 3 (corresponding to macroscopic grade 2), and 1 as Banff grade 2 (corresponding 
to macroscopic grade 1) skin rejection (Animals 2-4, Figure 1d). One systemically treated 
animal was classified as Banff grade 2 skin rejection, although no macroscopic lesions were 
detectable (Animal 12, Figure 1d). No significant differences were found between the 2 
groups in terms of lymphocyte infiltration (P=0.2415), vasculopathy (P=0.1411) or Banff 
grade (P=0.1660, Mann-Whitney test, Figure 1d). All observed rejection episodes were 
restricted to graft skin, with no signs of rejection in graft muscle (Figure S1, SDC, 
http://links.lww.com/TP/B584). However, TGMS-TAC-treated animals had significantly 
more pronounced atrophy of the muscle fibers as compared to systemic treatment (P=0.0079, 
Mann-Whitney test, Figure S1, SDC, http://links.lww.com/TP/B584).  
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As evident from Figure 1c, 2 rejection episodes in animal 2 markedly improved after TGMS-
TAC reinjection. The first one – macroscopic grade 1 at the time of reinjection – was 
completely reverted within a week. The second one – macroscopic grade 2 – required 2 to 3 
weeks to reduce to grade 1 (Figure 2) and within a month a complete recovery was observed, 
which, however, lasted only 3 weeks.  
 
Reduced systemic but relevant tissue TAC levels with TGMS-TAC 
To understand TAC distribution over time, TAC concentrations were measured in blood 
(biweekly), and in graft and contralateral limb skin (monthly). In blood, a burst release of 
TAC was detected in the first 72 h after the first TGMS-TAC injection. This peak was beyond 
the upper quantification limit of the LC-MS/MS analysis (ie, 65 ng/ml) during the first 24-48 
h, afterwards it normalized to therapeutic levels (5 – 20 ng/ml). At POD 46 most animals had 
subtherapeutic levels (<5 ng/ml). Compared to the first TGMS-TAC injection, the following 
injections induced markedly weaker burst releases, followed by similar TAC release kinetics 
(P<0.0001 for first peak versus second, P<0.0001 for first peak versus third, and P=0.0009 for 
second peak vs. third, standard one-way ANOVA, Figure 3a). Trough levels of systemically 
treated animals were within the therapeutic range throughout the duration of the experiments 
(Figure 3a). Biweekly average TAC levels in blood of TGMS-TAC and animals showed that 
TGMS-TAC-treated animals had significantly lower TAC blood levels compared with 
systemically treated animals (9.29 ± 5.89 vs. 13.44 ± 4.44 ng/ml, respectively, P=0.0060, 
Mann-Whitney test, Figure 3b). 
In TGMS-TAC-treated animals there was a nonsignificant trend towards higher TAC 
concentrations in the graft as compared to the contralateral limb skin during the first week, 
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corresponding to the burst release observed in blood (P=0.1532, paired t-test, Figure 4a). For 
the rest of the measured time points there were no statistically significant differences between 
TAC levels in graft and contralateral limb skin. In systemically treated animals there were no 
statistically significant differences between the TAC levels in graft and contralateral limb skin 
at all time points (Figure 4b). Monthly average skin TAC levels in TGMS-TAC graft skin 
were higher than in the respective contralateral limb skin (1.1 ± 1.49 ng/mg vs. 0.25 ± 0.19, 
respectively, P=0.0195, Figure 4c). Under systemic treatment there was no significant 
difference between graft and contralateral limb skin (0.46 ± 0.39 ng/mg vs. 
0.29 ± 0.16 ng/mg, respectively, P=0.1094, Wilcoxon test, Figure 4c). When compared 
between groups, TAC levels in both graft and contralateral limb skin were comparable 
(P=0.7785 and P=0.4755 respectively, Mann-Whitney test, Figure 4c). 
 
Low antidonor antibody and complement activation 
The formation of donor-specific antibody (DSA) was assessed by incubating donor 
thymocytes with plasma of transplanted animals and subsequent analysis by flow cytometry. 
There was no significant intergroup difference for binding of IgG to donor thymocytes, 
whereas IgM was significantly lower in the TGMS-TAC group at POD 280 as compared to 
systemic treatment (mean fluorescence – 75.56 ± 18.62 and 143.8 ± 41.09 respectively, 
P=0.013, Student‟s t-test, Figure 5a). At endpoint no significant antibody (IgG and IgM, 
Figure 5b) and complement (C4b/c, C5b-9, Figure S2, SDC, http://links.lww.com/TP/B584) 
deposition, or B cell infiltration was observed (CD45R, Figure S3, SDC, SDC, 
http://links.lww.com/TP/B584), except for increased C3b/c deposition under systemic 
treatment (integrated density 1018 ± 155.6 and 1500 ± 300.1 for TGMS-TAC and systemic 
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treatment respectively, P=0.029, Student‟s t-test, Figure S2, SDC, 
http://links.lww.com/TP/B584). 
 
TGMS-TAC mitigates immunosuppression-related side effects 
BUN in TGMS-TAC animals was higher than in naïve age-matched animals and lower than in 
systemically treated animals – 12.62 ± 1.6, 5.9 ± 0.2 and 20.86 ± 4.86 mmol/l, respectively 
(P=0.0023 TGMS-TAC vs. systemic treatment, P=0.0095 TGMS-TAC vs. naïve, and 
P<0.0001 systemic treatment vs. naïve, Figure 6a). Creatinine was lower in TGMS-TAC and 
naïve age-matched animals compared to systemic treatment (27.2 ± 4.21, 23.2 ± 2.68, and 
49.8 ± 17.08 μmol/l, respectively, P=0.0117 TGMS-TAC vs. systemic treatment, P=0.0039 
systemic treatment vs. naïve, Figure 6b). Histological analysis of kidneys revealed only 
minimal damage under both treatments (Figure S4, SDC, http://links.lww.com/TP/B584). 
Cholesterol was comparable between groups (2.48 ± 0.39, 2.35 ± 0.48, and 
2.88 ± 0.47 mmol/l for TGMS-TAC, systemic treatment, and naïve Lewis rats, respectively, 
Figure 6c). Triglycerides were similar in TGMS-TAC and naïve rats and decreased in 
systemic treatment group as compared to naïve rats (1.22 ± 0.54 mmol/l, 0.44 ± 0.29 mmol/l, 
and 1.75 ± 0.99 mmol/l for TGMS-TAC, systemic treatment and naïve Lewis rats 
respectively, P= 0.0236 between naïve rats and systemic treatment, Figure 6d).  
Hepatic enzymes were not significantly different between naïve rats and the 2 treatment 
groups. AST was 140.6 ± 97.18 U/L, 109 ± 52.72 U/L, and 80 ± 15.64 U/L for TGMS-TAC, 
systemic treatment, and naïve rats respectively, Figure 6e. ALT was 73.4 ± 29.57 U/L, 
48.4 ± 29 U/L, and 50.4 ± 7.8 U/L for TGMS-TAC, systemic treatment, and naïve rats 
respectively, Figure 6f).  
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The complete blood count of TGMS-TAC and systemically treated animals at endpoint was 
comparable to naïve age-matched rats, except for total hemoglobin, mean corpuscular 
hemoglobin, platelet distribution width, and median platelet volume, which were lower under 
systemic treatment, compared either to naïve animals or to both naïve and TGMS-TAC-
treated animals (one-way ANOVA, Table 1). 
As mentioned above, under systemic treatment 1 of the 6 animals was euthanized at POD 275, 
due to markedly enlarged ipsilateral inguinal lymph node, accompanied by elevated white 
blood cell count (75.1x10
3
 cells/μl) and apathetic behavior indicating pain and/or suffering. 
Histopathological analyses of the lymph node revealed aggressive lymphoma, most consistent 
with diffuse large B cell lymphoma (Figure 6g). Another animal from the same group had an 
increasingly firm and growing solid mass circumventing the graft, accompanied by a slow but 
steady increase of the white blood cell count until endpoint. Necropsy revealed a large 
encapsulated granuloma-like formation filled with granulated yellow-green substance. 
Histopathological analysis confirmed that the formation was an infected pseudo-cyst (Figure 
6h). PCR analyses of its content revealed Staphylococcus aureus and Proteus mirabilis, 
commensal skin bacteria. In the TGMS-TAC group neither malignant nor infectious 
complications were observed. 
 
TGMS-TAC therapy favors hematopoietic chimerism 
To understand the dynamics of Teff and Treg, and chimerism under both treatments we 
analyzed blood at selected time points throughout the study. The gating strategy for Teff and 
Treg enumeration is shown in Figure S5 (SDC, http://links.lww.com/TP/B584), and for 
chimerism – in Figure S6 (SDC, http://links.lww.com/TP/B584).  
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Both treatment groups had significantly decreased amounts of circulating T cells compared to 
naïve rats. Initially there were significantly more T cells in the TGMS-TAC group than in 
systemically treated group (for example in postoperative week 2: 2087 ± 427 T cells/μl 
vs.1163 ± 359 T cells/μl respectively – P=0.0074, Student‟s t-test). After 17 weeks of gradual 
decrease the difference of T cell counts between the TGMS-TAC and systemically treated 
group were no longer statistically significant (for example in postoperative week 19: 
1825 ± 767 T cells/μl vs. 1290 ± 336 T cells/μl, P=0.1486, Student‟s t-test, Figure 7a). Three 
T cell populations – cytotoxic T lymphocytes (CTL), T helper cells and Treg – were 
separately analyzed, with additional focus on Helios
+
 and Helios
-
 Treg populations. The 
T helper cells were the most abundant T cell population and followed the total T cell 
dynamics (Figure 7b). There were no major differences in the CTL or the Treg populations 
between the 2 treatment groups over time (Figure 7c-f, respectively).  
In terms of chimerism, in the first 11 weeks there was a significantly higher amount of 
circulating donor-derived cells in the TGMS-TAC group (Figure 8a). Donor-derived B cells, 
T helper cells, CTL, and monocytes were all significantly increased in the TGMS-TAC-
treated group compared to systemic treatment for up to 23 weeks (Figure 8b-e). Circulating 
donor-derived granulocytes were initially high in both treatment groups (for example in 
postoperative week 2: 367 ± 92 and 314 ± 113 donor-derived granulocytes/μl for TGMS-TAC 
and systemic treatment, respectively). This number dropped to 58 ± 52 and 90 ± 36 cells/μl, 
respectively, at postoperative week 10 and remained low until termination of the experiment 
(Figure 8f). At endpoint peripheral blood monocytes isolated from graft and contralateral limb 
skin of both groups were analyzed using the same flow cytometry protocol. The cell count 
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was low and revealed no significant differences between the 2 treatment groups (Figure S7, 
SDC, http://links.lww.com/TP/B584). 
 
Discussion 
Our data show that repeated intragraft injections of TGMS-TAC sustain long-term graft 
survival with better toxicological and immunological outcomes as compared to systemic TAC 
delivery. Markers of kidney function (ie, BUN and creatinine) and complete blood analysis at 
endpoint, showed preserved kidney and hematological parameters of TGMS-TAC-treated rats 
as compared to systemic treatment. Unlike humans
10
, rat models require sodium depletion in 
order to develop significant TAC-induced kidney damage
11-13
. Therefore, we speculate that 
the toxic effects reported in this study may be underrepresented, and that the TGMS-TAC 
treatment may potentially have more visible benefits in humans, especially in the kidney on a 
histological level.  
Our study was also of sufficient duration to reveal possible complications of long-term 
immunosuppression. One systemically treated animal developed an infected pseudo-cyst 
containing commensal skin bacteria. Another developed an aggressive lymphoma. 
Lymphomas can arise spontaneously in ageing Lewis rats; however, their incidence during the 
first year of life of a male Lewis rat is extremely low
14
, suggesting that systemic 
immunosuppression contributed to its development. Necropsy of TGMS-TAC-treated animals 
did not reveal any malignancy or opportunistic infection, suggesting that localized 
immunosuppression could mitigate immunosuppression-related complications.  
Local complications related to TGMS-TAC treatment, such as rash, alopecia, discoloration, 
atrophy or thinning of skin, or extracutaneous hydrogel extrusions were not observed. 
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Animals did not extensively groom or scratch the limb after injection indicating absence of 
local irritation. Stool was firm and urine was clear, suggesting no acute gastro-intestinal or 
renal complications resulting from TGMS-TAC either.  
While providing better recipient outcomes, TGMS-TAC treatment resulted in inferior graft 
outcomes as compared to systemic treatment. Four of the 6 TGMS-TAC treated animals 
experienced at least 1 rejection episode. Rejecting TGMS-TAC treated animals had 
comparable systemic TAC levels to the nonrejecting TGMS-TAC treated animals. Moreover, 
we
7
 and others
15
 have demonstrated that localized immunosuppression promotes extended 
rejection-free graft survival in the setting of subtherapeutic systemic TAC levels. Therefore, 
we hypothesize that these rejections are not due to subtherapeutic systemic TAC levels, but 
rather to low intragraft TAC levels. According to Capron et al, tissue levels of 
immunosuppression provide a more accurate insight into actual efficiency of 
immunosuppression
16
. Reinjecting TGMS-TAC guided by local TAC levels, instead of fixed 
time points, could mitigate the observed rejections. To test this hypothesis, we plan to conduct 
TGMS-TAC studies in a porcine VCA model. In addition to being more clinically relevant, 
pigs provide the opportunity to collect frequent biopsies, sufficient to identify minimal 
threshold for intragraft TAC levels. 
TGMS-TAC treated animals demonstrated increased muscle atrophy as compared to 
systemically treated animals. Calcineurin is involved in skeletal muscle hypertrophy and 
tacrolimus counteracts this effect
17
. However, to our knowledge, there have been no studies 
demonstrating that tacrolimus monotherapy causes direct myotoxicity, as conversely reported 
for tacrolimus in conjunction with statins
18
. Moreover, clinical cases of tacrolimus overdose 
have not reported effects on skeletal musculature
19
, suggesting that muscle atrophy is not 
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TAC related. Mechanical pressure of the hydrogel deposits on graft vessels or nerves resulting 
in muscle atrophy is not a likely explanation either, since grafts were all well-perfused and all 
animals used their limbs for walking until endpoint in both groups. The hydrogel itself has 
been previously described to be safe, biocompatible and biodegradable
7
. However, our data 
cannot rule out the possibility that muscle atrophy may be a hydrogel-related side effect, 
which could not develop in studies of shorter duration. Importantly, muscle atrophy is a 
known manifestation of chronic rejection, and we believe that this is the most likely 
explanation for our observations. Indeed, multiple acute rejection episodes have been 
correlated to chronic rejection, particularly in rat
20
. However, nonrejecting TGMS-TAC 
treated animals also had high muscle atrophy scores, keeping the question of muscle atrophy a 
matter requiring further investigation. 
A third and potentially problematic aspect of TGMS-TAC hydrogel could be the TAC burst 
release following TGMS-TAC injection. TGMS-TAC injections led to peaks in TAC blood 
levels that, with each subsequent injection, became significantly lower. Due to the enzyme 
responsiveness of the hydrogel, the most likely reason for the very high first peak is the 
elevated levels of inflammation-related enzymes resulting from the surgical trauma and 
ischemia-reperfusion injury. However, in our view, the burst release has arguably a negative 
impact, as high intragraft perioperative TAC levels were shown to prolong graft survival in 
the same experimental model
21
. 
Each TGMS-TAC injection contained 7 mg of TAC and the total amount of TAC given over 
280 days to TGMS-TAC-treated animals was 28 mg. In contrast, animals treated systemically 
with 1 mg TAC/kg/day received a total of 84 to 112 mg of TAC, depending on the weight of 
the rats, which ranged from 300 to 400 g. Consequently the systemic TAC levels in TGMS-
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TAC treated animals were significantly lower than the trough TAC levels in systemically 
treated animals. Nevertheless, TAC levels in skin were comparable between the 2 groups. 
Interestingly, while in nonrejecting TGMS-TAC treated animals TAC levels were similar in 
transplanted and contralateral limb skin, upon rejection levels increased in the transplanted 
limb as compared to nonrejecting grafts and contralateral limb skin (Figure S8, SDC, 
http://links.lww.com/TP/B584). This supports the idea that rejection triggers the local release 
of the drug. We also found that at endpoint systemically treated animals had significantly 
decreased tissue TAC levels (P<0.05 in graft and P<0.001 in contralateral limb skin as 
compared to previous time point by paired t-test). We do not have an explanation for this 
observation, as reduced systemic TAC levels, or any observable physiological changes, did 
not accompany it. 
In terms of immunological outcomes, the amount of circulating and intragraft Treg was 
comparable between TGMS-TAC and systemic treatment. However, TGMS-TAC treatment 
was associated with higher and more persistent hematopoietic chimerism compared to 
systemic treatment. Chimerism is a protolerogenic factor
22
 and boosting it without aggressive 
preconditioning or bone marrow transplantation may be an attractive option to control 
antigraft immunity in VCA. Despite elevated chimerism, most TGMS-TAC-treated animals 
experienced rejection episodes. Chimerism alone is not sufficient to prevent rejection and 
requires the support of higher Treg counts
23
, which was not the case under both treatments. 
Moreover, it has been shown that robust chimerism cannot prevent rejection once 
immunosuppression is tapered in a porcine VCA model
24
. The levels of chimerism in TGMS-
TAC-treated animals, despite being elevated compared to systemic treatment, were still below 
the threshold required for tolerance
25
. Therefore rejection due to reaching low intragraft TAC 
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levels was not preventable by the achieved increase in chimerism with TGMS-TAC. 
Nevertheless, the possibility to use localized immunosuppression to increase chimerism levels 
to the “tolerogenic threshold”25 represents an interesting opportunity that deserves further 
investigation. 
In 2014 for the first time the VCA society dealt with antibody-mediated rejection in a 
presensitized face recipient, raising patient sensitization as the next frontier in the field
26
. 
Recent studies in rat VCA model have clearly demonstrated that sensitized recipients 
experience accelerated rejection of both cell- and antibody-mediated nature
27
. In our study we 
have not included a presensitized group, neither did our animals develop de novo DSA. 
Complement deposition
28
, and tertiary lymphoid structure formation
29
, which were also 
described as participants in the VCA rejection process, were also not detected, consistent with 
previous studies
30
. Future studies addressing the efficacy of TGMS-TAC in a sensitized 
animal model would provide a strong argument on the potential and limitations of this 
therapeutic modality. 
In view of clinical application, a combination of “the best of both worlds” – combining use of 
reduced systemic immunosuppression and local „on demand‟ immunosuppression – might be 
envisaged to balance the outcomes of graft and recipient. Moreover, single-drug 
immunotherapies are not successful in clinical VCA. Multidrug immunosuppressive protocols 
are currently used in transplanted patients to guarantee an effective level of 
immunosuppression. Therefore, we believe that protocols involving localized 
immunosuppression in humans should further evolve by including multiple drugs to better 
control graft rejection. 
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In summary, this study demonstrates that the use of an enzyme-responsive drug delivery 
system for localized immunosuppression in VCA results in long-term graft survival with 
reduced drug-related side effects. These findings support the safety of this therapeutic 
possibility, and suggest a potential to mitigate immunosuppression-related morbidities in 
patients. 
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Figure legends: 
Figure 1 Long-term graft survival and graft histology are comparable between TGMS-
TAC and systemic tacrolimus treatment. (a) Experimental scheme of the 2 treatment groups. 
Group 1 – 1 ml hydrogel with 7 mg tacrolimus intragraft treated group (TGMS-TAC). Group 2 
daily systemic treatment with 1 mg/kg/day tacrolimus group (systemic tacrolimus), including 
treatment application frequencies and planned duration of the experiments. (b) Kaplan-Meier 
survival curve of TGMS-TAC-treated and systemic tacrolimus treated animals (n=6 / group). (c) 
Macroscopic grading of graft rejection over time in each of the rats (animals 1 to 6 – TGMS-
TAC treated, animals 7 to 12 – systemically treated). Appearance of edema and erythema are 
defined as grade 1, epidermolysis and exudation as grade 2, desquamation, necrosis and 
mummification as grade 3. TGMS-TAC reinjection time points are indicated. Animal 1 was 
euthanized at postoperative day 149 after reaching grade 3 rejection. (d) Representative 
histological Hematoxylin and Eosin stained sections of graft skin collected at endpoint – 
postoperative day (POD) 280 from both treatment groups and their corresponding 
histopathological evaluation. Intergroup differences of the results presented are not significant as 
evaluated by Mann-Whitney test. Individual values are presented as dots with indication of the 
mean values by lines. 
 
Figure 2 TGMS-TAC treatment does not completely prevent, but can revert rejection 
episodes. (a) Representative photographs of rejecting graft before (POD 204) and after 
(POD 234) TGMS-TAC reinjection and (b) corresponding histological Hematoxylin and Eosin 
stained sections of rejecting graft skin before and after TGMS-TAC reinjection. 
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Figure 3 Blood tacrolimus levels are lower with TGMS-TAC therapy. (a) Tacrolimus levels 
were measured by LC-MS/MS in blood of TGMS-TAC and systemic tacrolimus treated rats 
(trough levels) over time. TGMS-TAC reinjection time points are indicated by syringe symbols 
on the x-axis. Statistical analyses of the differences between the peaks of tacrolimus release 
under TGMS-TAC treatment are shown. Data are shown as individual values and means, 
***P<0.001, ****P<0.0001 by ordinary one-way ANOVA. Individual values have been 
manually shifted to left or right to make each value visible. (b) Mean biweekly tacrolimus blood 
levels between TGMS-TAC and systemic tacrolimus treated rats are compared. Each data point 
represents the mean value of pooled tacrolimus measurements acquired over the course of each 2 
consecutive weeks (starting from postoperative week 1 + 2, then 3 + 4 etc. until the end of the 
study). Statistical analyses of the differences between the 2 groups are shown. Data are presented 
as individual values, mean ± SD. are indicated, **P<0.01 by Mann-Whitney test. 
 
Figure 4 Tacrolimus levels in graft skin are higher with TGMS-TAC therapy. (a) LC-
MS/MS tacrolimus measurements in graft and contralateral limb skin biopsies of TGMS-TAC-
treated rats over time. TGMS-TAC reinjection time points are indicated. (b) LC-MS/MS 
tacrolimus measurements in graft and contralateral limb skin biopsies of systemic tacrolimus 
treated rats over time. Data are shown as individual values and means. Individual values have 
been manually shifted to left or right to make each value visible. (c) Mean tacrolimus levels in 
graft and contralateral limb skin of TGMS-TAC-treated or systemic tacrolimus treated animals. 
Each data point represents the mean value across the experimental group at each time point of 
tacrolimus measurements in either graft or contralateral limb skin. Statistical analyses of the 
differences between the 2 groups are shown. Data are shown as individual values, mean ± SD 
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are indicated, *P<0.05, Mann-Whitney test is used for comparisons between the 2 treatment 
groups, Wilcoxon test is used for comparisons within a group between the 2 sites of biopsy 
collections. 
 
Figure 5 Local and systemic tacrolimus treatment is associated with low donor-specific 
antibody (DSA) formation. (a) Levels of IgG and IgM DSA in the plasma of TGMS-TAC or 
systemic tacrolimus treated rats at POD 280. Donor-thymocytes have been incubated with heat-
inactivated recipients‟ plasma isolated at POD 280, followed by staining with anti-IgG and anti-
IgM antibody. DSA deposition on thymocytes have been analyzed by flow cytometry and 
expressed as mean fluorescence intensity (MFI). Lower threshold for positivity is defined as 
mean + 2x SD of the MFI measured in donor-thymocytes incubated with naïve Lewis rats‟ 
plasma. Data are shown as individual values, mean ± SD are depicted, *P<0.05 by Student‟s t-
test. (b) Representative results of immunostained graft skin and muscle cryosections with anti-
IgG or anti-IgM antibody and (c) their corresponding quantification. Data are shown as 
individual values, mean ± SD are depicted. Intergroup differences are not significant as 
evaluated by Student‟s t-test.  
 
Figure 6 TGMS-TAC treatment mitigates elevation of kidney function markers and 
occurrence of malignancy and opportunistic infections. (a-f) Biochemical analyses of the 
plasma levels of (a) blood urea nitrogen, (b) creatinine, (c) cholesterol, (d) triglycerides, (e) 
aspartate aminotransferase, (f) alanine aminotransferase in plasma collected at POD 280 from 
TGMS-TAC and systemic tacrolimus treated rats. Data are shown as individual values, 
mean ± SD are depicted, *P<0.05, **P<0.01, ****P<0.0001 by one-way ANOVA. (g) 
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Representative histological Hematoxylin and Eosin stained section of pseudocyst infected with 
Staphylococcus aureus and Proteus mirabilis in a systemic tacrolimus treated rat and of (h) 
ipsilateral inguinal lymph node with lymphoma in another systemic tacrolimus treated rat. 
 
Figure 7 TGMS-TAC treatment depletes T cells to a lesser extend than systemic TAC 
treatment. (a-f) Absolute number of T cell populations in blood of TGMS-TAC and systemic 
tacrolimus treatment at selected time points. The values measured in naïve animals are reported 
(black dots). Cells are enumerated by flow cytometry as (a) T cells (CD45
+
, CD3
+
), (b) 
Cytotoxic T cells (CD45
+
, CD3
+
, CD8
+
), (c) T helper cells (CD45
+
, CD3
+
, CD4
+
), (d) Treg cells 
(CD45
+
, CD3
+
, CD4
+
, FoxP3
+
, CD25
high
), (e) Helios
+
 Treg cells (CD45
+
, CD3
+
, CD4
+
, FoxP3
+
, 
CD25
high
,
 
Helios
+
), (f) Helios
-
 Treg cells (CD45
+
, CD3
+
, CD4
+
, FoxP3
+
, CD25
high
,
 
Helios
-
). Data 
are shown as mean ± SD. Statistical analyses between naïve and the 2 treatment groups - one-
way ANOVA. Highlighted in orange are the time points, which are significantly different 
between TGMS-TAC and systemic tacrolimus treatment groups. Significant differences between 
naïve animals and treated animals are not shown. 
 
Figure 8 TGMS-TAC boosts multilineage hematopoietic chimerism in blood. (a-f) Donor-
derived white blood cell populations in blood from TGMS-TAC and systemic tacrolimus at 
selected time points. The values measured in naïve animals (unspecific-staining) are reported 
(black dots). Donor cells are enumerated by flow cytometry as (a) all donor-derived white blood 
cells (CD45
+
, RT1a
+
), (b) donor-derived B cells (CD45
+
, CD3
-
, CD4
-
, SSC
low
, RT1a
+
), (c) 
donor-derived T helper cells (CD45
+
, CD3
+
, CD4
+
, RT1a
+
), (d) donor-derived cytotoxic T cells 
(CD45
+
, CD3
+
, CD8
+
, RT1a
+
), (e) donor-derived monocytes (CD45
+
, CD3
-
, CD4
+
, RT1a
+
), (f) 
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donor-derived granulocytes (CD45
+
, CD3
-
, CD4
-
, SSC
high
, RT1a
+). Naïve Lewis rats‟ white 
blood cells are RT1a
-
. Data are shown as mean ± SD. Statistical analyses between naïve and the 
2 treatment groups - one-way ANOVA. Highlighted in orange are the time points, which are 
significantly different between TGMS-TAC and systemic tacrolimus treatment groups. 
Significant differences between naïve animals and treated animals are not shown. 
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Table 1 Complete blood count of TGMS-TAC and systemic tacrolimus treated 
groups at POD 280 vs. naive age-matched animals 
 Naive Lewis 
rats (n=9) 
TGMS-TAC 
(n=5) 
Systemic 
tacrolimus 
(n=5) 
Significance 
WBC x 103  9.6 ± 0.9  7.4 ± 3.4  14.8 ± 15.1 ns 
RBC x 103  9.5 ± 0.9  10.1 ± 0.6  9.6 ± 0.3 ns 
HB g/dL  15.4 ± 0.4  15.8 ± 0.7  14.2 ± 0.7 †**, ‡**  
HCT %  50.4 ± 3.7  53.4 ± 3.3  49.9 ± 1.5 ns 
MCV fL  53.0 ± 2.0  53.1 ± 0.9  51.9 ± 2.1 ns 
MCH pg  16.3 ± 1.4  15.7 ± 0.6  14.8 ± 1.1 ns 
MCHC g/dL  30.7 ± 1.6  29.6 ± 1.0  28.5 ± 1.4 †* 
PLT x 103 709.2 ± 82.2 584.6 ±124.6 629.6 ±132.3 ns 
RDW_SD fL  28.5 ± 0.4  28.7 ± 0.5  28.4 ± 0.5 ns 
RDW_CV%  14.7 ± 2.0  14.9 ± 1.8  14.8 ± 2.1 ns 
PDW fL  11.1 ± 0.4  11.0 ± 0.7  10.0 ± 0.3 †**, ‡** 
MPV fL  8.2 ± 0.2  8.2 ± 0.3  7.7 ± 0.2 †**, ‡** 
 
WBC - white blood cells 
RBC - red blood cells 
HB - hemoglobin 
HCT - hematocrit 
MCV- mean corpuscular volume 
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MCH - mean corpuscular hemoglobin 
MCHC - mean corpuscular hemoglobin concentration 
PLT - platelets 
RDW - red blood cell distribution width 
PDW - platelet distribution width 
MPV - median platelet volume 
 
† Statistical significance between Naive Lewis rats and systemic tacrolimus 
treated group 
‡ Statistical significance between TGMS-TAC-treated group and systemic 
tacrolimus treated group 
* P<0.05 
** P<0.01 
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